POTENSI LUMBROKINASE DENGAN CARRIER N,N,N-TRIMETIL KITOSAN KLORIDA (TMC) MENGGUNAKAN LIGAND C-RGD SEBAGAI AGEN FIBRINOLITIK DAN ANTI-PLATELET TERBARUKAN

Naufal Nandita Firsty; Muhammad Furqan; Ilman Arif Aritonang

Naufal Nandita Firsty Pendidikan Dokter, Fakultas Kedokteran, Universitas Sumatera Utara, Medan
Muhammad Furqan Pendidikan Dokter, Fakultas Kedokteran, Universitas Sumatera Utara, Medan
Ilman Arif Aritonang Pendidikan Dokter, Fakultas Kedokteran, Universitas Sumatera Utara, Medan

Abstrak

Introduction: Venous thrombosis is the third most cardiovascular disease in the world. Administration of fibrinolytic agents such as streptokinase is the chosen treatment of the disease. However, the disadvantages are short half-time, unspecific to fibrin, poor targeting, expensive price, and tend to cause bleeding. Therefore another fibrinolytic agent is needed to cope with some of the deficiencies and side effects of current fibrinolytic agents. This literature review aims to explain the potential of lumbrokinase with TMC carrier and c-RGDligand as a renewable fibrinolytic and antiplatelet agent. The method used in this literature review is a literature study using the last 10 years of journal gained from some search engines such as ScienceDirect, PubMed, Google Scholar, and ClinicalKey.

Discussion: Lumbrokinase is an enzyme from the extraction of the earthworm’s digestive tract which consists of several serine protease isoenzymes. As a fibrinolytic agent, lumbrokinase can hydrolyze both fibrin or fibrinogen and also activate plasminogen into plasmin. Besides, lumbrokinase is known as has an antiplatelet effect as aspirin has. The use of TMC as the carrier can increase the bioavailability of lumbrokinase. Meanwhile, the addition of c-RGD ligand can increase the specificity preventing fibrinogen to bind the GPIIb/IIIa receptor thereby inhibiting thrombus formation.

Conclusion: From various in vitro and in vivo studies, it was concluded lumbrokinase with carrier TMC and c-RGD ligand can accelerate thrombolysis, and reduce the risk of bleeding so that it’s potentially a renewable fibrinolytic and antiplatelet agent. However, further research is needed regarding therapeutic doses, side effects, and toxicity studies.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Referensi

1. Shi A, Tao Z, Wei P, Zhao J. Epidemiological aspects of heart diseases (Review). Exp Ther Med. 2016;12(3):1645–50.
2. World Health Organization. 2016. Cardiovascular diseases (CVDs)[Internet]. Available from: https://www.who.int/news-room/fact sheets/detail/cardiovascular-diseases-(cvds)
3. Siddiqui T, Dikshit D. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. Current medicinal chemistry. 2013;20(22):2779
4. Kesieme, Kesieme. Deep vein thrombosis: a clinical review. J Blood Med [Internet]. 2011;59.
5. Andriani R, Wahid I. Defisiensi Protein S pada Trombosis Vena Dalam. J Kesehatan Andalas. 2018;7(Supplement 4):100–3.
6. Najihah.Penggunaan Compression Stocking Terhadap Pencegahan Deep Venous(DVT): Literatur Review. Journal of Islamic nursing. 2017;1(1): 0–4.
7. Ali MR, Salim Hossain M, Islam MA, Saiful Islam Arman M, Sarwar Raju G, Dasgupta P, et al. Aspect of thrombolytic therapy: A review. Sci World J. 2014;2014(1).
8. Darotin R, Nurdiana, Nasution TH. Analisis Faktor Prediktor Mortalitas Stroke Hemoragik di Rumah Sakit Daerah dr.Soebandi Jember. Nurseline J. 2017;2(1):1–10.
9. Center for Disease Control and Prevention. 2019.Data and Statistics on Venous Thromboembolism [Internet]. Available from : https://www.cdc.gov/ncbddd/dvt/data.html
10. European Thrombosis & Haemostasis Alliance. European Thrombosis & Haemostasis Alliance Consensus Statement. 2018;1-2.
11. Tambunan KL, Hutagalung EU, Sukrisman L, Saleh I, Gunawan SB, Sofyanuddin S, et al. Venous thromboembolism in 13 Indonesian patients undergoing major orthopedic surgery. Med J Indones. 2009;18(4):249.
12. Absar S, Nahar K, Kwon YM, et al. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.Pharmaceutical research. 2013;30(6):1663-1676.
13. Kim J-Y, Kim J-K, Park J-S, et al. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30(29):5751-5756.
14. Gayatri A, Purwantyastuti. Penggunaan Lumbrokinase sebagai Fibrinolitik dan Antitrombotik Oral. 2013;40(3):167–70.
15. Jin M, Jin G, Huang WEI, Gao Z. PEGylation of Lumbrokinase improves pharmacokinetic profile and enhances anti ‑ thrombotic effect in a rat carotid artery thrombosis model. 2017;4909–14.
16. Jin M, Chen W, Huang W, et al. Preparation of pegylated lumbrokinase and an evaluation of its thrombolytic activity both in vitro and in vivo. Acta Pharmaceutica Sinica B. 2013;3(2):123-129.
17. Quiñones JP, Peniche H, Peniche C. Chitosan based self-assembled nanoparticles in drug delivery. Polymers (Basel). 2018;10(3):1–32.
18. Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81(3):463–9.
19. Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z. Targeted thrombolysis by using c-RGD-modified N,N,N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm [Internet]. 2019;45(1):88–95. Available from: http://dx.doi.org/10.1080/03639045.2018.1522324
20. Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targetting by cyclic RGD - Modified liposomes. Journal of biomedical materials research Part A. 2010;93(3):1004-1015.
21. Verma MK, Pulicherla KK. Lumbrokinase - a potent and stable fibrin-specific plasminogen activator. Int J Bio-Science Bio-Technology. 2011;3(2):57–70.
22. Wang KY, Tull L, Cooper E, Wang N, Liu D. Recombinant Protein Production of Earthworm Lumbrokinase for Potential Antithrombotic Application. Evidence-Based Complement Altern Med. 2013;2013:1–8.
23. Xu Z rong, Yang Y mei, Gui Q feng, Zhang L na, Hu L. Expression, purification, and characterization of recombinant lumbrokinase PI239 in Escherichia coli. Protein Expr Purif [Internet]. 2010;69(2):198–203. Available from: http://dx.doi.org/10.1016/j.pep.2009.08.013
24. Antonino RSCMDQ, Fook BRPL, Lima VADO, Rached RÍDF, Lima EPN, Lima RJDS, et al. Preparation and characterization of chitosan obtained from shells of shrimp (Litopenaeus vannamei Boone). Mar Drugs. 2017;15(5):1–12.
25. Younes I, Rinaudo M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar Drugs. 2015;13(3):1133–74.
26. Ways TMM, Lau WM, Khutoryanskiy V V. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers (Basel). 2018;10(3).
27. Chen G, Svirskis D, Lu W, Ying M, Huang Y, Wen J. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. J Control Release [Internet]. 2018;277(March):142–53. Available from: https://doi.org/10.1016/j.jconrel.2018.03.013
28. Xu J, Xu B, Shou D, Xia X, Hu Y. Preparation and evaluation of vancomycin-loaded N-trimethyl chitosan nanoparticles. Polymers (Basel). 2015;7(9):1850–70.
29. Abdassah M. Nanopartikel Dengan Gelasi Ionik. Farmaka. 2012;15(1):45–52
30. Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine. 2013;8(5):773-784.
31. Pan Y, Wang X, Yin Z. Synthesis and evaluation of cationic polymeric micelles as carriers of lumbrokinase for targeted thrombolysis. Asian J Pharm Sci [Internet]. 2019;14(2):144–53. Available from: https://doi.org/10.1016/j.ajps.2018.03.004